Dacetuzumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD40 |
| Clinical data | |
| Other names | SGN-40 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6452H9964N1732O1998S42 |
| Molar mass | 145111.33 g·mol−1 |
  (what is this?) (verify) | |
This drug was developed by Seattle Genetics, Inc.
